CN204405679U - C reactive protein detection test strips and test card - Google Patents
C reactive protein detection test strips and test card Download PDFInfo
- Publication number
- CN204405679U CN204405679U CN201520103104.5U CN201520103104U CN204405679U CN 204405679 U CN204405679 U CN 204405679U CN 201520103104 U CN201520103104 U CN 201520103104U CN 204405679 U CN204405679 U CN 204405679U
- Authority
- CN
- China
- Prior art keywords
- determinand
- antibody
- test strips
- detection
- zone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010074051 C-Reactive Protein Proteins 0.000 title claims abstract description 35
- 102100032752 C-reactive protein Human genes 0.000 title claims abstract description 34
- 238000002331 protein detection Methods 0.000 title claims abstract description 16
- 238000001514 detection method Methods 0.000 claims abstract description 59
- 238000006243 chemical reaction Methods 0.000 claims abstract description 49
- 239000000463 material Substances 0.000 claims abstract description 44
- 229910052761 rare earth metal Inorganic materials 0.000 claims abstract description 42
- 239000002096 quantum dot Substances 0.000 claims abstract description 41
- 150000002910 rare earth metals Chemical class 0.000 claims abstract description 41
- 238000003908 quality control method Methods 0.000 claims abstract description 20
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 18
- 239000011616 biotin Substances 0.000 claims abstract description 9
- 229960002685 biotin Drugs 0.000 claims abstract description 9
- 235000020958 biotin Nutrition 0.000 claims abstract description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 7
- 108090001008 Avidin Proteins 0.000 claims abstract description 6
- 241001529936 Murinae Species 0.000 claims abstract description 4
- 239000002245 particle Substances 0.000 claims description 12
- 239000004005 microsphere Substances 0.000 claims description 9
- YBNMDCCMCLUHBL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-pyren-1-ylbutanoate Chemical compound C=1C=C(C2=C34)C=CC3=CC=CC4=CC=C2C=1CCCC(=O)ON1C(=O)CCC1=O YBNMDCCMCLUHBL-UHFFFAOYSA-N 0.000 claims description 3
- 229910004613 CdTe Inorganic materials 0.000 claims description 3
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 claims description 3
- GPXJNWSHGFTCBW-UHFFFAOYSA-N Indium phosphide Chemical compound [In]#P GPXJNWSHGFTCBW-UHFFFAOYSA-N 0.000 claims description 2
- 239000011806 microball Substances 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 abstract description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 150000002500 ions Chemical class 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 9
- 239000012530 fluid Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 8
- 229910052693 Europium Inorganic materials 0.000 description 7
- 238000013016 damping Methods 0.000 description 7
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 4
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 4
- 229910052747 lanthanoid Inorganic materials 0.000 description 4
- 150000002602 lanthanoids Chemical class 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229910052692 Dysprosium Inorganic materials 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229910052779 Neodymium Inorganic materials 0.000 description 3
- 229910052772 Samarium Inorganic materials 0.000 description 3
- 229910052771 Terbium Inorganic materials 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003365 glass fiber Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 3
- 229920006267 polyester film Polymers 0.000 description 3
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000001615 biotins Chemical class 0.000 description 2
- GHXRKGHKMRZBJH-UHFFFAOYSA-N boric acid Chemical compound OB(O)O.OB(O)O GHXRKGHKMRZBJH-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229910052691 Erbium Inorganic materials 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 229910052689 Holmium Inorganic materials 0.000 description 1
- 229910052765 Lutetium Inorganic materials 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 229910052777 Praseodymium Inorganic materials 0.000 description 1
- 229910052773 Promethium Inorganic materials 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229910052775 Thulium Inorganic materials 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229910052769 Ytterbium Inorganic materials 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
- 229910001940 europium oxide Inorganic materials 0.000 description 1
- AEBZCFFCDTZXHP-UHFFFAOYSA-N europium(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Eu+3].[Eu+3] AEBZCFFCDTZXHP-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052746 lanthanum Inorganic materials 0.000 description 1
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 229940100684 pentylamine Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical compound [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 description 1
- VQMWBBYLQSCNPO-UHFFFAOYSA-N promethium atom Chemical compound [Pm] VQMWBBYLQSCNPO-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- FRNOGLGSGLTDKL-UHFFFAOYSA-N thulium atom Chemical compound [Tm] FRNOGLGSGLTDKL-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- -1 velveteen Substances 0.000 description 1
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
Abstract
The utility model provides a kind of c reactive protein detection test strips, comprise the following assembly overlapping stickup successively: i) for adding determinand and making described determinand and the determinand application of sample reaction zone detecting reagent reacting, wherein said determinand application of sample reaction zone is coated with the first antibody that individually marked by quantum dot and rare-earth luminescent material and by biotin labeled second antibody, the different epi-positions of described first antibody and second antibody difference specific recognition c reactive protein, ii) for detecting the determinand detection zone whether described determinand exists, wherein said determinand detection zone has spaced detection zone and quality control band, described detection zone is fixed with Avidin, described quality control band is fixed with the antibody of against murine IgG, and iii) suction zones.Additionally provide a kind of c reactive protein detection test card.Test strips of the present utility model and test card have been taken into account the range of linearity of low value sensitivity and detection and can have been realized quick detection.
Description
Technical field
The utility model relates to a kind of c reactive protein detection test strips and test card.
Background technology
C reactive protein (C-reactive protein, CRP) refer to body be infected or tissue damage time blood plasma in the general designation of some protein sharply risen.C reactive protein can activating complement and strengthen cytophagous engulfing and play opsonic action, thus removes the invasion pathogenic microorganism of body and damage, and downright bad, the histocyte of apoptosis, plays important protective effect in the innate immunity process of body.In recent years, people recognize that the slight rising of the c reactive protein of normal level in original traditional sense is relevant to coronary artery events, apoplexy and peripheral angiopathy gradually, are independently hazards.By improving detection sensitivity, the quantitative measurement to hs-CRP can be realized.Namely hs-CRP detects is design for the c reactive protein concentration level of normal range 0-10.0mg/L, and higher to the accuracy requirement of low concentration, detection limit can reach 0.005mg/L-0.20mg/L.
Quantum dot size is between several nm to tens nm.It is normally made up of inorganic core and the organic molecule that is coated on core surface.For quantum dot, when its size reaches certain critical value, the behavior of material will present Quantum Properties, and the change from macroscopic view to microcosmic also will occur the structures and characteristics of material.Test strips based on the exploitation of quantum dot unique optical properties has possessed very high detection sensitivity, particularly be applicable to the Accurate Determining of low concentration level (as pg/ml-ng/ml) thing content to be checked, but its range of linearity detected is wide not, within the scope of identical a set of detection system, the accurate quantitative analysis of high level sample cannot be realized.Rare earth material fluorescence lifetime is long, emission spectrum is narrow, Stokes displacement large, is very beneficial for the many merits such as the interference of elimination background fluorescence and parasitic light.Therefore, when being used alone quantum dot, the detection sensitivity of low side and the wide range of linearity cannot be taken into account.And other to have fluorescent element or the fluorescent material of similar excitation wavelength and emission wavelength to quantum dot by use in conjunction, the wider range of linearity is obtained by being expected to, and can be implemented in the reading carrying out fluorescence signal result in same set of fluorescence detecting system, be also more conducive in clinical popularization and application.
Utility model content
technical matters
The detection demand fulfillment high sensitivity of c reactive protein, good linear scope, fast, the requirement such as convenient.Therefore, a kind of c reactive protein detection test strips and the test card that can meet the demand is needed.
technical scheme
On the one hand, the utility model provides a kind of c reactive protein detection test strips, it is characterized in that, described test strips comprises the following assembly overlapping stickup successively:
I) for adding determinand and making described determinand and the determinand application of sample reaction zone detecting reagent reacting, wherein said determinand application of sample reaction zone is coated with following detection reagent: the first antibody individually marked by quantum dot and rare-earth luminescent material and by biotin labeled second antibody, the different epi-positions of described first antibody and second antibody difference specific recognition c reactive protein
Ii) for detecting the determinand detection zone whether described determinand exists, wherein said determinand detection zone has spaced detection zone and quality control band, and described detection zone is fixed with Avidin, and described quality control band is fixed with the antibody of against murine IgG, and
Iii) suction zones.
In one embodiment, described test strips comprises the base plate being furnished with determinand application of sample reaction zone, determinand detection zone and suction zones further.
In one embodiment, described quantum dot is microspheres form and has the particle size range of 2nm-30nm, and described quantum dot is selected from following group: CdTe, CdSe, PbSe, InP and GaN.
In one embodiment, described determinand application of sample reaction zone is coated with microballoon further, and wherein said micro-ball load has described rare-earth luminescent material and described first antibody.
In one embodiment, the particle size of described microballoon is 50nm-400nm.
In one embodiment, the particle size of described microballoon is 100nm-300nm.
In one embodiment, the particle size of described microballoon is 100nm or 300nm.
On the other hand, the utility model provides a kind of c reactive protein detection test card, and it is characterized in that, described test card comprises with lower part:
I) test strips described in aforementioned any one embodiment, and
The shell of the test strips ii) described in coated aforementioned any one embodiment, wherein said shell comprises:
Ii-1) Ka Gai of well and detect aperture is provided with, wherein said well is opened on the upside of described determinand application of sample reaction zone, to expose the subregion of described determinand application of sample reaction zone, described detect aperture is opened on the upside of described determinand detection zone, to expose the Zone Full of described detection zone and described quality control band, and
Ii-2) base be connected to each other with described Ka Gai.
beneficial effect
In test strips of the present utility model, use in conjunction quantum dot and rare-earth luminescent material, the problem that the fabulous low value sensitivity overcoming application quantum dot or rare-earth luminescent material existence separately and the detection range of linearity cannot be taken into account; By introducing biotin-labeled pentylamine Cascaded amplification system, further increase detection sensitivity; The design of application of sample reaction zone is more simple compared to the design of independent sample application zone and reaction zone, significantly simplifies production technology and flow process; The design of test strips shape and structure has been taken into full account and has made test strips have application space widely by the needs being read result by fluorescence detector; Be easy to carry about with one with reagent card, preserve and reading in fluorescence detector.
Accompanying drawing explanation
The schematic side view of Fig. 1 c reactive protein detection of the present utility model test strips;
The schematic top plan view of Fig. 2 c reactive protein detection of the present utility model test strips; With
The schematic diagram of Fig. 3 c reactive protein detection of the present utility model test card.
Reference numeral:
The region of the corresponding detection zone of 1 base plate 6 quality control band 11
The region of the corresponding quality control band of 2 determinand application of sample reaction zone 7 base 12
3 determinand detection zone 8 Ka Gai
4 suction zones 9 wells
5 detection zone 10 detect aperture
Embodiment
Hereinafter come with reference to the accompanying drawings to describe illustrative embodiments in more detail.Described accompanying drawing is used for illustrating the utility model, but not is limited.
Fig. 1 is the schematic side view of c reactive protein detection test strips of the present utility model.
As shown in Figure 1, test strips of the present utility model comprises base plate 1 and on base plate 1, overlaps the determinand application of sample reaction zone 2 of stickup, determinand detection zone 3 and suction zones 4 successively.
Determinand application of sample reaction zone 2 is for receiving determinand and determinand and the association reaction of coated antibody on it subsequently.Test strips of the present utility model be applicable to detect determinand include but not limited to serum, blood plasma, urine.The design of application of sample reaction zone is more simple compared to the design of independent sample application zone and reaction zone, significantly simplifies production technology and flow process.
Determinand application of sample reaction zone 2 is coated with following detection reagent further: the first antibody individually marked by quantum dot and rare-earth luminescent material and by biotin labeled second antibody, the different epi-positions of described first antibody and second antibody specific recognition c reactive protein respectively.
In the utility model, term " mark " comprises employing chemistry or physical method makes the first antibody of anti-c reactive protein directly be connected with quantum dot and rare-earth luminescent material.But mark also can be completed by alternate manner, the first antibody of such as rare-earth luminescent material and anti-c reactive protein is by such as embedding or the mode of load on microballoon reach the object of " mark " simultaneously.Therefore, in one embodiment, determinand application of sample reaction zone 2 can have microballoon (not shown) further, on described microballoon, embedding or load have the first antibody of rare-earth luminescent material and anti-c reactive protein simultaneously.In one embodiment, embedding or can have chemistry between the rare-earth luminescent material of load on described microballoon and the first antibody of anti-c reactive protein and connect, such as, be present on described microballoon with the form of the first antibody of the anti-c reactive protein of rare-earth luminescent material mark.In another embodiment, embedding or can not have chemistry between the rare-earth luminescent material of load on described microballoon and the first antibody of anti-c reactive protein and connect, namely on described microballoon, embedding or load have to each other without the rare-earth luminescent material of chemistry connection and the first antibody of anti-c reactive protein.In rear a kind of embodiment, determinand application of sample reaction zone 2 has by the first antibody of quantum dot-labeled anti-c reactive protein, and the rare-earth luminescent material of load on microballoon and the first antibody of anti-c reactive protein.
In one embodiment, described microballoon can be polymer microballoon, such as polystyrene microsphere.In one embodiment, the particle size scope of microballoon, between 50nm-400nm, preferably between 100nm-300nm, is more preferably 100nm or 300nm.
The method preparing rare-earth fluorescent microballoon is that prior art is known, includes but not limited to: investment, namely in the polymerization process of polymer microballoon, adds rare earth material complex; Bonding method, even if there is coordination reaction in the functional group on rare earth element ion and polymer lateral chain obtains rare-earth fluorescent microballoon; And swelling method and cladding process.Latter two method is all on the basis of monodispersed microballoon (as: polystyrene microsphere), by the infiltration of rare earth material complex or the inside or the surface that are coated on microballoon, by controlling reaction conditions, can realize finally preparing the polymer microballoon that monodispersity is good, fluorescence intensity is high, fluorescent stability is good.
Quantum dot is made up of semiconductor material, stable diameter at the nano particle of 2nm-30nm, usually present microspheroidal.Quantum dot is adopted to carry out degree of accuracy and the sensitivity that labelled antibody can improve detection greatly.In one embodiment, described quantum dot has the particle diameter of 2nm-30nm.In one embodiment, described quantum dot has the particle diameter of 2nm-20nm.In a preferred embodiment, described quantum dot has the particle diameter of 5nm-20nm.In one embodiment, described quantum dot is II-VI group quantum dot (as CdTe, CdSe etc.).In another embodiment, described quantum dot is iii-v quantum dot (as InP, GaN etc.).In another embodiment, described quantum dot is group IV-VI quantum dot (as PbSe etc.).
Rare-earth luminescent material comprises lanthanide series-lanthanum (La) in the periodic table of chemical element, cerium (Ce), praseodymium (Pr), neodymium (Nd), promethium (Pm), samarium (Sm), europium (Eu), gadolinium (Gd), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er), thulium (Tm), ytterbium (Yb), lutetium (Lu), and with closely-related two the element-scandiums (Sc) of 15 elements of group of the lanthanides and yttrium (Y) totally 17 kinds of elements.Relative to traditional fluorescent material, rare-earth luminescent material has the spectrum that receptivity is strong, conversion ratio is high and can launch from ultraviolet to infra-red range, has very strong emissive ability in visible region, and the advantages such as stable physical property.In one embodiment, described rare-earth luminescent material is one or several in fluorescent material containing the various lanthanide series such as europium (Eu) ion, terbium (Tb) ion, samarium (Sm) ion, neodymium (Nd) ion, dysprosium (Dy) ion.In another embodiment, rare-earth luminescent material is that one or several in rare-earth luminescent material containing the various lanthanide series such as europium (Eu) ion, terbium (Tb) ion, samarium (Sm) ion, neodymium (Nd) ion, dysprosium (Dy) ion load to the rare-earth fluorescent microballoon that microballoon is formed.Rare-earth luminescent material is loaded to the stability that microballoon can further improve fluorescence.
In test strips of the present utility model, the antibody of rare-earth luminescent material mark makes the range of linearity detected can cover high level region, and quantum dot-labeled antibody is conducive to the detection of low value to reach the requirement of sensitivity simultaneously.The coupling of quantum dot and rare-earth luminescent material makes test strips of the present utility model can realize the requirement of high sensitivity and the wide detection range of linearity simultaneously.
The determinand detection zone 3 whether existed for detecting described determinand has spaced detection zone 5 and quality control band 6, and detection zone 5 is fixed with Avidin, and quality control band 6 is fixed with the antibody of against murine IgG.Test strips of the present utility model adopts the design of biotin-avidin Cascaded amplification detection system carry out quantitative measurement to c reactive protein, drastically increase the sensitivity of detection thus.Detection zone 5 and quality control band 6 spaced apart, distance can between 0.05cm to 0.8cm.In one embodiment, be interposed between detection zone 5 and quality control band 6 between 0.1cm to 0.6cm, preferably between 0.3cm to 0.5cm.Quality control band 6 its for determining whether reaction system is set up.
The power that suction zones 4 provides determinand to move from 2 to determinand detection zone 3, determinand application of sample reaction zone by capillary action.Suction zones 4 can be made up of the such as material such as velveteen, glass by being selected from, and is preferably made up of cotton-wool material.
The entire length of test strips is between 8cm to 10cm, and overall width, between 0.2cm to 0.5cm, preferably between 0.2cm to 0.3cm, most preferably is 0.3cm.Test strips of the present utility model is being provided sensitivity and while detecting the range of linearity, can reduced the consumption of antibody, greatly saved production cost by the length and/or width reducing test strips.
Fig. 2 is the schematic top plan view of test strips of the present utility model.Part identical with Fig. 1 in Fig. 2 repeats no more.
Fig. 3 is the schematic diagram of c reactive protein detection test card of the present utility model.As shown in Figure 3, test card of the present utility model comprises the shell of aforesaid test strips and coated aforesaid test strips, and wherein said shell comprises the card lid 8 being provided with well 9 and detect aperture 10, and the base 7 be connected to each other with card lid 8.Well 9 is opened on the upside of determinand application of sample reaction zone 2, and to expose the subregion of determinand application of sample reaction zone 2, detect aperture 10 is opened on the upside of determinand detection zone 3, to expose the Zone Full of detection zone 5 and quality control band 6.
Card lid 8 and base 7 all can be made up of such as plastic or other material.Well 9 and detect aperture 10 can be square, rectangle, trapezoidal, oval, circular, etc. shape.The lengthwise of well 9 can be 0.05cm to 0.6cm, preferred 0.1cm to 0.5cm.Growing crosswise of well 9 can be 0.15cm to 0.45cm, preferred 0.2cm to 0.4cm.The lengthwise of detect aperture 10 can be 0.8cm to 2.5cm, preferred 1.0cm to 2.3cm.Growing crosswise of detect aperture 10 can be 1.2cm to 2.1cm, preferred 1.5cm to 1.9cm.
C reactive protein detection test card of the present utility model has important clinical meaning, and it makes the detection of c reactive protein can carry out in corresponding fluorescence detector, can realize large batch of sample thus and detect fast.The part that Fig. 3 and Fig. 1 and 2 is identical repeats no more.
Test strips provided by the utility model has taken into account the range of linearity of low value sensitivity and detection, and can realize quick, single part and quantitatively detect, in addition volume little, be easy to carry about with one and preserve, for Clinical practice provides great convenience.Especially, the design of the test card coordinated with test strips makes large batch of sample detect fast becomes possibility, is conducive to large-scale promotion application, possesses wide market outlook.
Embodiment
In following embodiment, described c reactive protein first antibody, c reactive protein second antibody, dynamics, Avidin, biotin, quantum dot, rare-earth europium fluorescent microsphere, europium oxide (Eu
2o
3), 4,4'-bis-(1,1', 2,2', 3, the fluoro-4' of 3'-seven, 6'-acetyl butyryl-6'-base)-chlorine sulphonyl-ortho-terphenyl (BHHCT), 2-(N-morpholine) ethyl sulfonic acid (MES), carbodiimide (EDC), N-hydroxy-succinamide (NHS), dimethyl formamide (DMF), N, N'-dicyclohexylcarbodiimide (DCC), pyridine, bovine serum albumin(BSA) (BSA), Tween-20, trehalose, Superdex200 filler, glass fibre element film, polyester film, nitrocellulose filter, high-intensity water absorbent paper is commercially available prod.
The test strips of described use in conjunction quantum dot and rare-earth luminescent material and the preparation method of test card are:
1) preparation of application of sample reaction zone
The pre-service of A, application of sample reaction zone
Glass fibre element film or polyester film are put into the pretreatment fluid (0.1M containing 1%BSA and 0.1%Tween-20, boric acid-the borate buffer solution of pH8.0-8.6 or the 0.05M containing 1%BSA and 0.1%Tween-20, the Tris-HCl damping fluid of pH7.4-8.2) middle after immersion treatment 3-5 hour, in 35-39 DEG C of air dry oven, dry 3-5 hour.
The preparation of B, quantum dot-labeled antibody
Use 0.05M, 2-(N-morpholine) ethyl sulfonic acid (MES) activation buffer of pH4.5-5.0 washs the quantum dot containing carboxylic group in modified surface, adding carbodiimide (EDC) and N-hydroxy-succinamide (NHS) makes the two final concentration be 15-60mmol, room temperature reaction 20-30 minute, abundant washing quantum dot, with 0.05M, the C reaction first antibody that same buffer was dialysed is added after boric acid-borate buffer solution redissolution of pH8.0-8.6, the mass ratio of first antibody and quantum dot is made to be 1:5 to 1:25, room temperature reaction is after 2 hours, add the 0.02M containing 10%BSA, the phosphate buffer room temperature of pH7.2-7.6 closes 30 minutes, abundant washing quantum dot, with the 0.05M containing 1%BSA and 0.1%Tween-20, the conserving liquid of the Tris-HCl damping fluid of pH7.4-8.2 redissolves to original volume.
The preparation (1) of C, rare-earth luminescent material labelled antibody
Eu is dissolved with 6M HCl
2o
3, and be settled to final concentration 1mg/ml with ultrapure water, then use 0.05MpH8.0NH
4hCO
3solution dilution 500 times.By BHHCT anhydrous alcohol solution to final concentration 10mg/ml.Use the carbonate mark damping fluid of 0.05-0.2M, pH9.0-9.5 to c reactive protein first antibody dialysis 4-6 time, or ultrafiltration centrifugation is washed 4-6 time, adjustment concentration is to 0.25mg/ml.Add in first antibody solution by BHHCT ethanol solution with the ratio of volume ratio 1:200, room temperature lucifuge continues mixing reaction 1-3 hour.Use 0.05M pH8.0NH
4hCO
3solution desalination.Use Superdex200 filler purifying bond in 1*30cm post, with 0.1%BSA solution equilibria 1-3 hour, with 0.05M Tris-HCl wash-out, flow velocity is 1ml/min.Protein peak is collected, with 0.22 μm of filter aseptic filtration according to 280nm absorbance.Dilute 20 times with 0.05M Tris-HCl again, add Eu afterwards
3+nH
4hCO
3solution, the ratio being 1:5 to 1:15 according to volume ratio is added, and room temperature lucifuge continues mixing reaction 1-2 hour.Clean with 0.05M Tris-HCl with ultrafiltration centrifugation and be concentrated into antibody concentration and be greater than 5mg/ml, for subsequent use.
The preparation (2) of D, rare-earth luminescent material labelled antibody
Use 0.05M, the rare-earth europium fluorescent microsphere of 2-(N-morpholine) ethyl sulfonic acid (MES) the activation buffer washing of pH4.5-5.0, adding carbodiimide (EDC) and N-hydroxy-succinamide (NHS) makes the two final concentration be 15-60mmol, room temperature reaction 20-30 minute, abundant washing rare-earth europium fluorescent microsphere, with 0.05M, the first antibody of dialysing is added after boric acid-borate buffer solution redissolution of pH8.0-8.6, the mass ratio of c reactive protein first antibody and fluorescent microsphere is made to be 1:8 to 1:60, room temperature reaction is after 2 hours, add the 0.02M containing 10%BSA, the phosphate buffer room temperature of pH7.2-7.6 closes 30 minutes, abundant washing rare-earth europium fluorescent microsphere, with the 0.05M containing 1%BSA and 0.1%Tween-20, the conserving liquid of the Tris-HCl damping fluid of pH7.4-8.2 redissolves to original volume.
The mixing of E, quantum dot-labeled antibody and rare-earth luminescent material labelled antibody
The rare-earth luminescent material labelled antibody prepared in the quantum dot-labeled antibody prepared in the step B of this part and step C or step D is mixed in the ratio that antibody concentration is 1:5 to 5:1, namely prepares the double-tagging potpourri of the quantum dot-labeled antibody of associating and rare-earth luminescent material labelled antibody.
The preparation of F, biotinylated antibody
By c reactive protein second antibody with phosphate buffer 4 DEG C of dialysed overnight of 0.02M, pH7.2-7.6, adjustment concentration is 5mg/ml-10mg/ml.
The pre-activate of biotin: accurately take 300mg biotin and be dissolved in the dimethyl formamide (DMF) of 8ml, the N-hydroxy-succinamide (NHS) of 183mg is added under room temperature condition, the N of 304mg, the pyridine of N'-dicyclohexylcarbodiimide (DCC) and 0.1ml, at room temperature stirs 24 hours by reaction mixture.Cross the urea filtering reaction and produce, by silica gel chromatography after filtrate is concentrated, the white solid that recrystallization obtains in isopropyl alcohol is preactivated biotin.
Preactivated biotin is dissolved with dimethyl formamide (DMF), its final concentration is made to be 0.05M, and join in the second antibody of dialysing, the mol ratio of second antibody and biotin is made to be 1:10-1:25, room temperature reaction 1 hour, with phosphate buffer 4 DEG C of dialysed overnight of 0.02M, pH7.2-7.6.
The preparation of G, application of sample reaction zone
The biotinylated antibody that quantum dot-labeled antibody this part step e prepared and the double-tagging potpourri of rare-earth luminescent material labelled antibody and step F prepare fully mixes, use and quantitatively spray film instrument with on the plain film of the glass fibre that 2 μ l/cm-8 μ l/cm even application are pretreated in the steps A of this part or polyester film, in 35-39 DEG C of air dry oven, dry 2-4 hour, add drying agent and seal up for safekeeping for subsequent use.
2) preparation of detection zone
The preparation of A, detection zone: use the coating buffer (0.01-0.02M containing 0.1-10% trehalose, the Tris-HCl damping fluid of pH7.4-8.2) Avidin is diluted to the concentration of 1mg/ml-5mg/ml, use quantitatively spray film instrument with 1.2 μ l/cm even application on nitrocellulose filter, in 35-39 DEG C of air dry oven, dry 2-4 hour.
The preparation of B, quality control band: use the coating buffer (0.01-0.02M containing 0.1-10% trehalose, the Tris-HCl damping fluid of pH7.4-8.2) anti-mouse IgG is diluted to the concentration of 0.5mg/ml-3mg/ml, use quantitatively spray film instrument with 0.8 μ l/cm even application on nitrocellulose filter, in 35-39 DEG C of air dry oven, dry 2-4 hour.
The preparation of C, detection zone: with the confining liquid (0.01-0.02M containing 1-10%BSA and 1-10% trehalose, the Tris-HCl damping fluid of pH7.4-8.2) by the cellulose nitrate membrane closure 1-2 hour containing detection zone and quality control band, take out in rearmounted 35-39 DEG C air dry oven and dry 2-4 hour, envelope is for subsequent use.
3) assembling of test strips
Be less than 30% in humidity, under temperature 20-30 DEG C of condition, carry out the assembling of test strips.Base plate selects PVC material, connects in turn and the partly overlapping application of sample reaction zone of adjacent regions, detection zone and suction zones in the direction of base plate the same face.When detection zone covers base plate, the position of detection zone is near application of sample reaction zone, and the position of quality control band is near suction zones.Suction zones is high-intensity water absorbent paper.Test strips is cut into after assembling.
4) assembling of test card
Be less than 30% in humidity, under temperature 20-30 DEG C of condition, carry out the assembling of test card.Above-mentioned test strips is placed in the centre position of plastic feet, the base plate of test strips is connected with plastic feet, and fastens plastic clip lid.Card covers and is provided with well and detect aperture, and well is opened on the upside of application of sample reaction zone, exposes the subregion of application of sample reaction zone, and detect aperture is opened on the upside of described detection zone, exposes the Zone Full of detection zone and quality control band.
5) mensuration of calibration object and measuring samples
The standard items of 100 μ l or measuring samples are joined the well of test card, carry out immunochromatography reaction, after 10-15 minute, test card is placed in special fluorescence detector, carry out quantitative measurement by the size reading fluorescence signal.
Above embodiment is only used to done citing is clearly described, the restriction not to embodiment.
Claims (8)
1. a c reactive protein detection test strips, is characterized in that, described test strips comprises the following assembly overlapping stickup successively:
I) for adding determinand and making described determinand and the determinand application of sample reaction zone detecting reagent reacting, wherein said determinand application of sample reaction zone is coated with following detection reagent: the first antibody individually marked by quantum dot and rare-earth luminescent material and by biotin labeled second antibody, the different epi-positions of described first antibody and second antibody difference specific recognition c reactive protein
Ii) for detecting the determinand detection zone whether described determinand exists, wherein said determinand detection zone has spaced detection zone and quality control band, and described detection zone is fixed with Avidin, and described quality control band is fixed with the antibody of against murine IgG, and
Iii) suction zones.
2. test strips as claimed in claim 1, is characterized in that, described test strips comprises the base plate being furnished with determinand application of sample reaction zone, determinand detection zone and suction zones further.
3. test strips as claimed in claim 1, it is characterized in that, described quantum dot is microspheres form and has the particle size range of 2nm-30nm, and described quantum dot is selected from following group: CdTe, CdSe, PbSe, InP and GaN.
4. test strips as claimed in claim 1, it is characterized in that, described determinand application of sample reaction zone is coated with microballoon further, and wherein said micro-ball load has described rare-earth luminescent material and described first antibody.
5. test strips as claimed in claim 4, it is characterized in that, the particle size of described microballoon is 50nm-400nm.
6. test strips as claimed in claim 5, it is characterized in that, the particle size of described microballoon is 100nm-300nm.
7. test strips as claimed in claim 6, it is characterized in that, the particle size of described microballoon is 100nm or 300nm.
8. a c reactive protein detection test card, is characterized in that, described test card comprises with lower part:
I) test strips according to any one of claim 1-7, and
The shell of the test strips ii) according to any one of coated claim 1-7, wherein said shell comprises:
Ii-1) Ka Gai of well and detect aperture is provided with, wherein said well is opened on the upside of described determinand application of sample reaction zone, to expose the subregion of described determinand application of sample reaction zone, described detect aperture is opened on the upside of described determinand detection zone, to expose the Zone Full of described detection zone and described quality control band, and
Ii-2) base be connected to each other with described Ka Gai.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201520103104.5U CN204405679U (en) | 2015-02-12 | 2015-02-12 | C reactive protein detection test strips and test card |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201520103104.5U CN204405679U (en) | 2015-02-12 | 2015-02-12 | C reactive protein detection test strips and test card |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN204405679U true CN204405679U (en) | 2015-06-17 |
Family
ID=53429529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201520103104.5U Expired - Fee Related CN204405679U (en) | 2015-02-12 | 2015-02-12 | C reactive protein detection test strips and test card |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN204405679U (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105548535A (en) * | 2016-01-21 | 2016-05-04 | 成都微瑞生物科技有限公司 | Classical swine fever antibody detection card and preparation method thereof |
| CN106622416A (en) * | 2017-03-13 | 2017-05-10 | 航天神舟生物科技集团有限公司 | Microfluidic paper chip for detection on human hypersensitive C-reactive protein, preparation method thereof and kit |
| CN106771239A (en) * | 2016-12-16 | 2017-05-31 | 威海纽普生物技术有限公司 | Serum amyloid A protein/Procalcitonin/C reactive proteins are three-in-one to determine kit and preparation method |
-
2015
- 2015-02-12 CN CN201520103104.5U patent/CN204405679U/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105548535A (en) * | 2016-01-21 | 2016-05-04 | 成都微瑞生物科技有限公司 | Classical swine fever antibody detection card and preparation method thereof |
| CN106771239A (en) * | 2016-12-16 | 2017-05-31 | 威海纽普生物技术有限公司 | Serum amyloid A protein/Procalcitonin/C reactive proteins are three-in-one to determine kit and preparation method |
| CN106622416A (en) * | 2017-03-13 | 2017-05-10 | 航天神舟生物科技集团有限公司 | Microfluidic paper chip for detection on human hypersensitive C-reactive protein, preparation method thereof and kit |
| CN106622416B (en) * | 2017-03-13 | 2019-04-09 | 航天神舟生物科技集团有限公司 | A kind of detection hs-CRP micro-fluidic paper chip and preparation method thereof and kit |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN204405678U (en) | For the test strips of joint-detection cardiac muscle troponin I-myoglobins-creatine kinase isozyme | |
| CN204228717U (en) | Procalcitonin quantitatively detects fluorescence immune chromatography reagent card | |
| Weng et al. | Highly luminescent CdTe quantum dots prepared in aqueous phase as an alternative fluorescent probe for cell imaging | |
| CN204405679U (en) | C reactive protein detection test strips and test card | |
| CN102359958B (en) | Kit and method for detecting procalcitonin | |
| KR101039629B1 (en) | Detection method of bio material, fabrication method of chip for detection of bio material, and chip for detection of bio material | |
| CN100367034C (en) | Method for measuring immunologic colloidal gold particle fluorescence quenching | |
| CN101339135B (en) | Method for promoting biological detection sensitivity by photon crystal | |
| CN105233892A (en) | Magnetic particle chemiluminescence double-layer micro-fluidic chip used for whole-blood sample detection | |
| CN105259163A (en) | Magnetic particle direct chemiluminiscence microfluidic chip for whole blood sample testing | |
| CA2575852A1 (en) | Lateral flow system and assay | |
| CN105259164A (en) | Micro-fluidic chip for multi-object quantitative detection based on magnetic particle chemiluminescence | |
| CN204228722U (en) | Based on test strips and the test card of two particle diameter fluorescent microsphere | |
| CN109541202A (en) | A kind of detection anti-HBs kit and preparation method thereof | |
| CN107449898B (en) | Kanamycin residue fluorescence immunochromatographic test paper and preparation method thereof | |
| CN103487578A (en) | CRP (C-reactive protein)/PCT (procalcitonin) combined diagnosis test paper and preparation method thereof | |
| CN105242047A (en) | Aflatoxin B1 graphene oxide immunochromatographic test strip and application thereof | |
| CN104374909A (en) | Chloramphenicol quantitative detection method based on up-conversion phosphor technology and immunochromatography technology | |
| CN105467117A (en) | Fast and quantitative PG (pepsinogen)II detection kit, production method thereof and PGII detection method | |
| CN204228723U (en) | The reagent strip of quantitative detection N terminal brain natriuretic peptide and reagent card | |
| CN101363861A (en) | Hepatitis b virus surface antigen chemiluminescence immune assay determination kit and method for preparing same | |
| CN110095596A (en) | Chemiluminescence based on Fe-MOFs-fluorescence double-bang firecracker answers immunosensor | |
| CN204405680U (en) | Detect the test strips of Procalcitonin | |
| CN204405682U (en) | The test card of use in conjunction quantum dot and rare-earth luminescent material | |
| CN110237865A (en) | It is a kind of load silver orthophosphate keratin nanometer floral material and its preparation and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180614 Address after: 225300 Taizhou, Jiangsu, China, west side of Tai Chi Road, China's medicine, building G59, 63 to three, west of Lu Jia Lu. Patentee after: JIANGSU DAJUN BIOTECHNOLOGY Co.,Ltd. Address before: 100176 Beijing city Daxing District economic and Technological Development Zone Hongda North Road 12 innovation building B block 3 District 210 Patentee before: ABZYMO BIOSCIENCES Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150617 |